, Volume 5, Issue 3, pp 443–457 | Cite as

Tau-based treatment strategies in neurodegenerative diseases

Review Article


Neurofibrillary tangles are a characteristic hallmark of Alzheimer’s and other neurodegenerative diseases, such as Pick’s disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). These diseases are summarized as tauopathies, because neurofibrillary tangles are composed of intracellular aggregates of the microtubule-associated protein tau. The molecular mechanisms of tau-mediated neurotoxicity are not well understood; however, pathologic hyperphosphorylation and aggregation of tau play a central role in neurodegeneration and neuronal dysfunction. The present review, therefore, focuses on therapeutic approaches that aim to inhibit tau phosphorylation and aggregation or to dissolve preexisting tau aggregates. Further experimental therapy strategies include the enhancement of tau clearance by activation of proteolytic, proteasomal, or autophagosomal degradation pathways or anti-tau directed immunotherapy. Hyperphosphorylated tau does not bind microtubules, leading to microtubule instability and transport impairment. Pharmacological stabilization of microtubule networks might counteract this effect. In several tauopathies there is a shift toward four-repeat tau isoforms, and interference with the splicing machinery to decrease four-repeat splicing might be another therapeutic option.

Key Words

Tau Alzheimer’s disease phosphorylation aggregation neurodegeneration therapy 


  1. 1.
    Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975;72: 1858–1862.PubMedGoogle Scholar
  2. 2.
    Cleveland DW, Hwo SY, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 1977;116: 207–225.PubMedGoogle Scholar
  3. 3.
    Drubin DG, Caput D, Kirschner MW. Studies on the expression of the microtubule-associated protein, tau, during mouse brain development, with newly isolated complementary DNA probes. J Cell Biol 1984;98: 1090–1097.PubMedGoogle Scholar
  4. 4.
    Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985;101: 1371–1378.PubMedGoogle Scholar
  5. 5.
    Kirschner M, Mitchison T. Beyond self-assembly: from microtubules to morphogenesis. Cell 1986;45: 329–342.PubMedGoogle Scholar
  6. 6.
    Caceres A, Kosik KS. Inhibition of neurite polarity by tau anti-sense oligonucleotides in primary cerebellar neurons. Nature 1990;343: 461–463.PubMedGoogle Scholar
  7. 7.
    Sheetz MP, Vale R, Schnapp B, et al. Vesicle movements and microtubule-based motors. J Cell Sci Suppl 1986;5: 181–188.PubMedGoogle Scholar
  8. 8.
    Sloboda RD, Rudolph SA, Rosenbaum JL, Greengard P. Cyclic AMP-dependent endogenous phosphorylation of a microtubule-associated protein. Proc Natl Acad Sci U S A 1975;72: 177–181.PubMedGoogle Scholar
  9. 9.
    Mandell JW, Banker GA. Microtubule-associated proteins, phosphorylation gradients, and the establishment of neuronal polarity. Perspect Dev Neurobiol 1996;4: 125–135.PubMedGoogle Scholar
  10. 10.
    Lee G, Cowan N, Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988;239: 285–288.PubMedGoogle Scholar
  11. 11.
    Schweers O, Schönbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for β-structure. J Biol Chem 1994; 269: 24290–24297.PubMedGoogle Scholar
  12. 12.
    Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry 1992;31: 10626–10633.PubMedGoogle Scholar
  13. 13.
    Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989;3: 519–526.PubMedGoogle Scholar
  14. 14.
    Preuss U, Biemat J, Mandelkow EM, Mandelkow E. The ‘jaws’ model of tau-microtubule interaction examined in CHO cells. J Cell Sci 1997;110: 789–800.PubMedGoogle Scholar
  15. 15.
    Butner KA, Kirschner MW. Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 1991;115: 717–730.PubMedGoogle Scholar
  16. 16.
    Goode BL, Feinstein SC. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol 1994;124: 769–782.PubMedGoogle Scholar
  17. 17.
    Panda D, Samuel JC, Massie M, Feinstein SC, Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Natl Acad Sci U S A 2003;100: 9548–9553.PubMedGoogle Scholar
  18. 18.
    Nothias F, Boyne L, Murray M, Tessler A, Fischer I. The expression and distribution of tau proteins and messenger RNA in rat dorsal root ganglion neurons during development and regeneration. Neuroscience 1995;66: 707–719.PubMedGoogle Scholar
  19. 19.
    Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993;11: 153–163.PubMedGoogle Scholar
  20. 20.
    Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993;10: 1089–1099.PubMedGoogle Scholar
  21. 21.
    Hirokawa N, Shiomura Y, Okabe S. Tau proteins: the molecular structure and mode of binding on microtubules. J Cell Biol 1988; 107: 1449–1459.PubMedGoogle Scholar
  22. 22.
    Chen J, Kanai Y, Cowan NJ, Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 1992;360: 674–677.PubMedGoogle Scholar
  23. 23.
    Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 1996;17: 1201–1207.PubMedGoogle Scholar
  24. 24.
    Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 2004; 279: 17957–17962.PubMedGoogle Scholar
  25. 25.
    Selden SC, Pollard TD. Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments. J Biol Chem 1983;258: 7064–7071.PubMedGoogle Scholar
  26. 26.
    Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer’s disease. J Cell Biol 1998; 143: 777–794.PubMedGoogle Scholar
  27. 27.
    Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003;24: 1079–1085.PubMedGoogle Scholar
  28. 28.
    Scitz A, Kojima H, Oiwa K, Mandelkow EM, Song YH, Mandelkow E. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 2002;21: 4896–4905.Google Scholar
  29. 29.
    Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008; 319: 1086–1089.PubMedGoogle Scholar
  30. 30.
    Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002;156: 1051–1063.PubMedGoogle Scholar
  31. 31.
    Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 2007;27: 2896–2907.PubMedGoogle Scholar
  32. 32.
    Brion JP, Flament-Durand J, Dustin P. Alzheimer’s disease and tau proteins. Lancet 1986;2(8515): 1098.PubMedGoogle Scholar
  33. 33.
    Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084–6089.PubMedGoogle Scholar
  34. 34.
    Hirano A. Hirano bodies and related neuronal inclusions. Neuropathol Appl Neurobiol 1994;20: 3–11.PubMedGoogle Scholar
  35. 35.
    Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 2006;26: 475–483.PubMedGoogle Scholar
  36. 36.
    Berry RW, Quinn B, Johnson N, Cochran EJ, Ghoshal N, Binder LI. Pathological glial tau accumulations in neurodegenerative disease: review and case report. Neurochem Int 2001;39: 469–479.PubMedGoogle Scholar
  37. 37.
    Thal DR, Holzer M, Rüb U, et al. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol 2000;163: 98–110.PubMedGoogle Scholar
  38. 38.
    Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006;9: 101–124.PubMedGoogle Scholar
  39. 39.
    Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased β-amyloid1–42 in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2001;71: 401–403.PubMedGoogle Scholar
  40. 40.
    Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26: 231–245.PubMedGoogle Scholar
  41. 41.
    Sjögren M, Minthon L, Davidsson P, et al. CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;107: 563–579.PubMedGoogle Scholar
  42. 42.
    Formichi P, Battisti C, Radi E, et al. Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer’s disease. J Cell Physiol 2006;208: 39–46.PubMedGoogle Scholar
  43. 43.
    Ganzer S, Arlt S, Schoder V, et al. CSF-tau, CSF-Aβ1–42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer’s disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 2003;110: 1149–1160.PubMedGoogle Scholar
  44. 44.
    Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2: 605–613.PubMedGoogle Scholar
  45. 45.
    Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer’s disease: perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004;111: 247–272.PubMedGoogle Scholar
  46. 46.
    Diniz BS, Pinto JA Jr, Forlenza OV. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008 Jan 29 (Epub ahead of print).Google Scholar
  47. 47.
    Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69: 2205–2212.PubMedGoogle Scholar
  48. 48.
    Buerger K, Ewers M, Andreasen N, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005;65: 1502–1503.PubMedGoogle Scholar
  49. 49.
    Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355: 2652–2663.PubMedGoogle Scholar
  50. 50.
    Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55: 306–319.PubMedGoogle Scholar
  51. 51.
    Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia [Erratum in: Ann Neurol 1998;44:428]. Ann Neurol 1998;43: 815–825.PubMedGoogle Scholar
  52. 52.
    Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393: 702–705.PubMedGoogle Scholar
  53. 53.
    Spillantini MG, Murrell JR, Goedert M, Fallow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998;95: 7737–7741.PubMedGoogle Scholar
  54. 54.
    Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 1998;437: 207–210.PubMedGoogle Scholar
  55. 55.
    Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998;282: 1914–1917.PubMedGoogle Scholar
  56. 56.
    Dayanandan R, Van Slegtenhorst M, Mack TG, et al. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett 1999;446: 228–232.PubMedGoogle Scholar
  57. 57.
    Nacharaju P, Lewis J, Easson C, et al. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 1999;447: 195–199.PubMedGoogle Scholar
  58. 58.
    Goedert M, Jakes R, Crowther RA. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett 1999;450: 306–311.PubMedGoogle Scholar
  59. 59.
    Gamblin TC, King ME, Dawson H, et al. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 2000; 39: 6136–6144.PubMedGoogle Scholar
  60. 60.
    Barghom S, Zheng-Fischhöfer Q, Ackmann M, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 2000; 39: 11714–11721.Google Scholar
  61. 61.
    D’Souza I, Poorkaj P, Hong M, et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A 1999; 96: 5598–5603.PubMedGoogle Scholar
  62. 62.
    Grover A, DeTure M, Yen SH, Hutton M. Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci Lett 2002;323: 33–36.PubMedGoogle Scholar
  63. 63.
    Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8: 711–715.PubMedGoogle Scholar
  64. 64.
    Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56: 1702–1706.PubMedGoogle Scholar
  65. 65.
    Togo T, Sahara N, Yen SH, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002;61: 547–556.PubMedGoogle Scholar
  66. 66.
    Anderton BH, Betts J, Blackstock WP, et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp 2001;(67):73-80.Google Scholar
  67. 67.
    Khlistunova I, Biemat J, Wang Y, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281: 1205–1214.PubMedGoogle Scholar
  68. 68.
    Eckermann K, Mocanu MM, Khlistunova I, et al. The β-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 2007;282: 31755–31765.PubMedGoogle Scholar
  69. 69.
    Mocanu MM, Nissen A, Eckermann K, et al. The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 2008;28: 737–748.PubMedGoogle Scholar
  70. 70.
    Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 2007;18: 5060–5068.PubMedGoogle Scholar
  71. 71.
    Steinhilb ML, Dias-Santagata D, Mulkearns EE, et al. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res 2007;85: 1271–1278.PubMedGoogle Scholar
  72. 72.
    Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004;116: 671–682.PubMedGoogle Scholar
  73. 73.
    Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309: 476–481.PubMedGoogle Scholar
  74. 74.
    Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33: 95–130.PubMedGoogle Scholar
  75. 75.
    Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm 2005;112: 813–838.PubMedGoogle Scholar
  76. 76.
    Yang YC, Lin CH, Lee EH. Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite formation through microtubule depolymerization by SGK1 and by SGK1 phosphorylation of tau. Mol Cell Biol 2006;26: 8357–8370.PubMedGoogle Scholar
  77. 77.
    Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997;89: 297–308.PubMedGoogle Scholar
  78. 78.
    Kishi M, Pan YA, Crump JG, Sanes JR. Mammalian SAD kinases are required for neuronal polarization. Science 2005;307: 929–932.PubMedGoogle Scholar
  79. 79.
    Pei JJ, Khatoon S, An WL, et al. Role of protein kinase B in Alzheimer’s neurofibrillary pathology. Acta Neuropathol 2003; 105: 381–392.PubMedGoogle Scholar
  80. 80.
    Pei JJ, Braak H, An WL, et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer’s disease. Brain Res Mol Brain Res 2002;109: 45–55.PubMedGoogle Scholar
  81. 81.
    Illenberger S, Zheng-Fischhöfer Q, Preuss U, et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease. Mol Biol Cell 1998;9: 1495–1512.PubMedGoogle Scholar
  82. 82.
    Morishima-Kawashima M, Hasegawa M, Takio K, et al. Hyperphosphorylation of tau in PHF. Neurobiol Aging 1995;16: 365–371; discussion 371–380.PubMedGoogle Scholar
  83. 83.
    Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 2002; 103: 26–35.PubMedGoogle Scholar
  84. 84.
    Drewes G, Trinczek B, Illenberger S, et al. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark): a novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J Biol Chem 1995;270: 7679–7688.PubMedGoogle Scholar
  85. 85.
    Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003;39: 409–421.PubMedGoogle Scholar
  86. 86.
    Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999;38: 3549–3558.PubMedGoogle Scholar
  87. 87.
    Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 2006;16: 230–241.PubMedGoogle Scholar
  88. 88.
    Kosik KS, Ahn J, Stein R, Yeh LA. Discovery of compounds that will prevent tau pathology. J Mol Neurosci 2002;19: 261–266.PubMedGoogle Scholar
  89. 89.
    Mandelkow EM, Thies E, Trinczek B, Biemat J, Ikow E. MARK/PARI kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 2004;167: 99–110.PubMedGoogle Scholar
  90. 90.
    Biemat J, Wu YZ, Timm T, et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell 2002;13: 4013–4028.Google Scholar
  91. 91.
    Timm T, Li XY, Biernat J, et al. MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. EMBO J 2003;22: 5090–5101.PubMedGoogle Scholar
  92. 92.
    Chin JY, Knowles RB, Schneider A, Drewes G, Mandelkow EM, Hyman BT. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol 2000;59: 966–971.PubMedGoogle Scholar
  93. 93.
    Matenia D, Griesshaber B, Li XY, et al. PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell 2005;16: 4410–4422.PubMedGoogle Scholar
  94. 94.
    Draviam VM, Stegmeier F, Nalepa G, et al. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol 2007;9: 556–564.PubMedGoogle Scholar
  95. 95.
    Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 2007;26: 2005–2014.PubMedGoogle Scholar
  96. 96.
    Toshima J, Toshima JY, Takeuchi K, Mori R, Mizuno K. Cofilin phosphorylation and actin reorganization activities of testicular protein kinase 2 and its predominant expression in testicular Sertoli cells. J Biol Chem 2001;276: 31449–31458.PubMedGoogle Scholar
  97. 97.
    Johne C, Matenia D, Li XY, Timm T, Balusamy K, Mandelkow EM. Spredl and TESK1: two new interaction partners of the kinase MARKK/TAO1 that link the microtubule and actin cytoskeleton. Mol Biol Cell 2008;19: 1391–1401.PubMedGoogle Scholar
  98. 98.
    LaLonde DP, Brown MC, Bouverat BP, Turner CE. Actopaxin interacts with TESK1 to regulate cell spreading on fibronectin. J Biol Chem 2005;280: 21680–21688.PubMedGoogle Scholar
  99. 99.
    Tsumura Y, Toshima J, Leeksma OC, Ohashi K, Mizuno K. Sprouty-4 negatively regulates cell spreading by inhibiting the kinase activity of testicular protein kinase. Biochem J 2005;387: 627–637.PubMedGoogle Scholar
  100. 100.
    Heredia L, Helguera P, de Olmos S, et al. Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid β-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer’s disease. J Neurosci 2006;26: 6533–6542.PubMedGoogle Scholar
  101. 101.
    Meijer L, Thunnissen AM, White AW, et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000;7: 51–63.PubMedGoogle Scholar
  102. 102.
    Zheng-Fischhöfer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kmase-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 1998;252: 542–552.PubMedGoogle Scholar
  103. 103.
    Liu SJ, Zhang JY, Li HL, et al. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 2004;279: 50078–50088.PubMedGoogle Scholar
  104. 104.
    Shuntoh H, Sakamoto N, Matsuyama S, et al. Molecular structure of the Cβ catalytic subunit of rat cAMP-dependent protein kinase and differential expression of Cα and Cβ isoforms in rat tissues and cultured cells. Biochim Biophys Acta 1992;1131: 175–180.PubMedGoogle Scholar
  105. 105.
    Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowbum RF. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer’s disease neurofibrillary degeneration. Brain Res 1998;797: 267–277.PubMedGoogle Scholar
  106. 106.
    Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by in. Nature 2000;405: 360–364.PubMedGoogle Scholar
  107. 107.
    Noble W, Olm V, Takata K, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003;38: 555–565.PubMedGoogle Scholar
  108. 108.
    Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003;40: 471–483.PubMedGoogle Scholar
  109. 109.
    Lopes JP, Oliveira CR, Agostinho P. Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-β and prion peptides: implications for Alzheimer’s disease and prion-related encephalopathies. Cell Mol Neurobiol 2007;27: 943–957.PubMedGoogle Scholar
  110. 110.
    Morfini G, Szebenyi G, Brown H, et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 2004;23: 2235–2245.PubMedGoogle Scholar
  111. 111.
    Hallows JL, Chen K, DePinho RA, Vincent I. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 2003;23: 10633–10644.PubMedGoogle Scholar
  112. 112.
    Johnson K, Liu L, Majdzadeh N, et al. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs. J Neurochem 2005;93: 538–548.PubMedGoogle Scholar
  113. 113.
    Camins A, Verdaguer E, Folch J, Canudas AM, Pallàs M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 2006;19: 453–460.PubMedGoogle Scholar
  114. 114.
    Rosania GR, Merlie J Jr, Gray N, Chang YT, Schultz PG, Heald R. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc Natl Acad Sci U S A 1999;96: 4797–4802.PubMedGoogle Scholar
  115. 115.
    Tsai LH. The inducible p25 transgenic mouse as an Alzheimer’s disease model. Presented at: Alzheimer’s disease: from molecular mechanisms to drug discovery, Cancun, Mexico, Dec 11–17, 2004.Google Scholar
  116. 116.
    Higuchi M, Iwata N, Saido TC. Understanding molecular mechanisms of proteolysis in Alzheimer’s disease: progress toward therapeutic interventions. Biochim Biophys Acta 2005;1751: 60–117.PubMedGoogle Scholar
  117. 117.
    Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A. The therapeutic potential of the calpain family: new aspects. Drug Discov Today 2006;11: 917–923.PubMedGoogle Scholar
  118. 118.
    Vita M, Abdel-Rehim M, Olofsson S, et al. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005;25: 91–103.PubMedGoogle Scholar
  119. 119.
    Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 1991;200: 564–577.PubMedGoogle Scholar
  120. 120.
    Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol 2001;65: 391–426.PubMedGoogle Scholar
  121. 121.
    Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003;116: 1175–1186.PubMedGoogle Scholar
  122. 122.
    Lovestone S, Reynolds CH, Latimer D, et al. Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994;4: 1077–1086.PubMedGoogle Scholar
  123. 123.
    Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997;272: 19547–19553.PubMedGoogle Scholar
  124. 124.
    Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer’s disease-like tau protein phosphorylation in neurons. FEBS Lett 1997;411: 183–188.PubMedGoogle Scholar
  125. 125.
    Li T, Paudel HK. Glycogen synthase kinase 3β phosphorylates Alzheimer’s disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 2006;45: 3125–3133.PubMedGoogle Scholar
  126. 126.
    Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 1997;56: 70–78.PubMedGoogle Scholar
  127. 127.
    Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002;34: 509–519.PubMedGoogle Scholar
  128. 128.
    Hernández F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J Neurochem 2002;83: 1529–1533.PubMedGoogle Scholar
  129. 129.
    Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 2001;20: 27–39.PubMedGoogle Scholar
  130. 130.
    Alvarez G, Munoz-Montaño JR, Satrústegui J, Avila J, Bogónez E, Díaz-Nido J. Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium: possible implications for Alzheimer’s disease. Bipolar Disord 2002;4: 131.Churcher I.Google Scholar
  131. 131.
    Churcher I. Tau therapeutic strategies for the treatment of Alzheimer’s disease. Curr Top Med Chem 2006;6: 579–595.PubMedGoogle Scholar
  132. 132.
    Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278: 45937–45945.PubMedGoogle Scholar
  133. 133.
    Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41: 789–813.PubMedGoogle Scholar
  134. 134.
    Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 2005;102: 6990–6995.PubMedGoogle Scholar
  135. 135.
    Sun L, Liu SY, Zhou XW, et al. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 2003;118: 1175–1182.PubMedGoogle Scholar
  136. 136.
    Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp Neurol 2001;168: 402–412.PubMedGoogle Scholar
  137. 137.
    Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 1995;65: 732–738.PubMedGoogle Scholar
  138. 138.
    Pei JJ, Gong CX, An WL, et al. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer’s disease. Am J Pathol 2003;163: 845–858.PubMedGoogle Scholar
  139. 139.
    Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004;566: 261–269.PubMedGoogle Scholar
  140. 140.
    Kampers T, Friedhoff P, Biemat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett 1996; 399: 344–349.PubMedGoogle Scholar
  141. 141.
    Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996;383: 550–553.PubMedGoogle Scholar
  142. 142.
    Arrasate M, Pérez M, Valpuesta JM, Avila J. Role of glycosaminoglycans in determining the helicity of paired helical filaments. Am J Pathol 1997;151: 1115–1122.PubMedGoogle Scholar
  143. 143.
    Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid β peptides: in vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am J Pathol 1997;150: 2181–2195.PubMedGoogle Scholar
  144. 144.
    von Bergen M, Friedhoff P, Biemat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of t protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming β structure. Proc Natl Acad Sci U S A 2000;97: 5129–5134.Google Scholar
  145. 145.
    von Bergen M, Barghom S, Li L, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local β-structure. J Biol Chem 2001;276: 48165–48174.Google Scholar
  146. 146.
    Mandelkow E, von Bergen M, Biemat J, Mandelkow EM. Structural principles of tau and the paired helical filaments of Alzheimer’s disease. Brain Pathol 2007; 17: 83–90.PubMedGoogle Scholar
  147. 147.
    Wille H, Drewes G, Biemat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 1992;118: 573–584.PubMedGoogle Scholar
  148. 148.
    Avila J, Santa-Maria I, Pérez M, Hernández F, Moreno F. Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol 2006;2006: 74539.PubMedGoogle Scholar
  149. 149.
    Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2006;3: 449–463.PubMedGoogle Scholar
  150. 150.
    Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 2005;64: 104–112.PubMedGoogle Scholar
  151. 151.
    Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A 2007;104: 10252–10257.PubMedGoogle Scholar
  152. 152.
    Bandyopadhyay B, Li G, Yin H, Kuret J. Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem 2007; 282: 16454–16464.PubMedGoogle Scholar
  153. 153.
    Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996;93: 11213–11218.PubMedGoogle Scholar
  154. 154.
    Pickhardt M, Gazova Z, von Bergen M, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer’s paired helical filaments in vitro and in cells. J Biol Chem 2005;280: 3628–3635.PubMedGoogle Scholar
  155. 155.
    Pickhardt M, Larbig G, Khlistunova I, et al. Phenylthiazolylhydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 2007;46: 10016–10023.PubMedGoogle Scholar
  156. 156.
    Bulic B, Pickhardt M, Khlistunova I, et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 2007;46: 9215–9219.PubMedGoogle Scholar
  157. 157.
    Pickhardt M, Biemat J, Khlistunova I, et al. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr Alzheimer Res 2007;4: 397–402.PubMedGoogle Scholar
  158. 158.
    Meyer B, Klein J, Mayer M, et al. Saturation transfer difference NMR spectroscopy for identifying ligand epitopes and binding specificities. Ernst Schering Res Found Workshop 2004;(44): 149–167.Google Scholar
  159. 159.
    Zeiger E, Shelby MD, Ivett J, McFee AF. Mutagenicity testing of 5-(4-nitrophenyl)-2,4-pentadien-1-al (spy dust) and its metabolites in vitro and in vivo. Environ Mutagen 1987;9: 269–280.PubMedGoogle Scholar
  160. 160.
    Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y; Diabetic Neuropathy Study Group in Japan. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. J Diabetes Complications 1996;10: 168–172.PubMedGoogle Scholar
  161. 161.
    Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 2005;44: 10227–10237.PubMedGoogle Scholar
  162. 162.
    Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 2004;43: 2879–2887.PubMedGoogle Scholar
  163. 163.
    Honson NS, Jensen JR, Darby MV, Kuret J. Potent inhibition of tau fibrillization with a multivalent ligand. Biochem Biophys Res Commun 2007;363: 229–234.PubMedGoogle Scholar
  164. 164.
    May BC, Fafarman AT, Hong SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Roc Natl Acad Sci U S A 2003;100: 3416–3421.Google Scholar
  165. 165.
    Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 2007;282: 10311–10324.PubMedGoogle Scholar
  166. 166.
    Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002;11: 1107–1117.PubMedGoogle Scholar
  167. 167.
    Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290: 1717–1721.PubMedGoogle Scholar
  168. 168.
    Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003;278: 25009–25013.PubMedGoogle Scholar
  169. 169.
    Berger Z, Ravikumar B, Menzies FM, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006;15: 433–442.PubMedGoogle Scholar
  170. 170.
    Tan JM, Wong ES, Kirkpatrick DS, et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 2008;17: 431–439.PubMedGoogle Scholar
  171. 171.
    Rubinsztein DC, Ravikumar B, Acevedo-Arozena A, Imarisio S, O’Kane CJ, Brown SD. Dyneins, autophagy, aggregation and neurodegeneration. Autophagy 2005;1: 177–178.PubMedGoogle Scholar
  172. 172.
    Rubinsztein DC, DiFiglia M, Heintz N, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 2005;1: 11–22.PubMedGoogle Scholar
  173. 173.
    Dickey CA, Dunmore J, Lu B, et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/ Thr sites but not KXGS (MARK) sites. FASEB J 2006;20: 753–755.PubMedGoogle Scholar
  174. 174.
    Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10: 283–290.PubMedGoogle Scholar
  175. 175.
    Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 2006;281: 10825–10838.PubMedGoogle Scholar
  176. 176.
    Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 1993;10: 1151–1160.PubMedGoogle Scholar
  177. 177.
    Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004;279: 4869–4876.PubMedGoogle Scholar
  178. 178.
    Dickey CA, Yue M, Lin WL, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci 2006;26: 6985–6996.PubMedGoogle Scholar
  179. 179.
    Petrucelli L, Dickson D, Kehoe K, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 2004;13: 703–714.PubMedGoogle Scholar
  180. 180.
    Sahara N, Murayama M, Mizoroki T, et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 2005;94: 1254–1263.PubMedGoogle Scholar
  181. 181.
    Kumar P, Ambasta RK, Veereshwarayya V, et al. CHIP and HSPs interact with β-APP in a proteasome-dependent manner and influence Aβ metabolism. Hum Mol Genet 2007;16: 848–864.PubMedGoogle Scholar
  182. 182.
    Karsten SL, Sang TK, Gehman LT, et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 2006;51: 549–560.PubMedGoogle Scholar
  183. 183.
    Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, Fontana A. Puromycin-sensitive aminopeptidase: sequence analysis, expression, and functional characterization. J Biol Chem 1995;270: 26931–26939.PubMedGoogle Scholar
  184. 184.
    Hersh LB. Characterization of membrane-bound aminopeptidases from rat brain: identification of the enkephalin-degrading aminopeptidase. J Neurochem 1985;44: 1427–1435.PubMedGoogle Scholar
  185. 185.
    Sengupta S, Horowitz PM, Karsten SL, et al. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 2006;45: 15111–15119.PubMedGoogle Scholar
  186. 186.
    Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates β-amyloid-induced neurodegeneration. J Neurosci 2005;25: 5365–5375.PubMedGoogle Scholar
  187. 187.
    Gamblin TC, Chen F, Zambrano A, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci U S A 2003;100: 10032–10037.PubMedGoogle Scholar
  188. 188.
    Rissman RA, Poon WW, Blurton-Jones M, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004;114: 121–130.PubMedGoogle Scholar
  189. 189.
    Fasulo L, Ugolini G, Cattaneo A. Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J Alzheimers Dis 2005;7: 3–13.PubMedGoogle Scholar
  190. 190.
    Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates Aβ oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 2006;281: 20315–20325.PubMedGoogle Scholar
  191. 191.
    Nerenberg ST, Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 1975;86: 887–898.PubMedGoogle Scholar
  192. 192.
    Broadwell RD, Sofroniew MV. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 1993;120: 245–263.PubMedGoogle Scholar
  193. 193.
    Zlokovic BV, Segal MB, Davson H, Lipovac MN, Hyman S, McComb JG. Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barriers. Endocrinol Exp 1990;24: 9–17.PubMedGoogle Scholar
  194. 194.
    Poduslo JF, Curran GL. Amyloid β peptide as a vaccine for Alzheimer’s disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport 2001;12: 3197–3200.PubMedGoogle Scholar
  195. 195.
    LaRue B, Hogg E, Sagare A, et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer’s Tg2576 mice. J Neurosci Methods 2004;138: 233–242.PubMedGoogle Scholar
  196. 196.
    Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27: 9115–9129.PubMedGoogle Scholar
  197. 197.
    Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63: 1459–1467.PubMedGoogle Scholar
  198. 198.
    Andoh T, Kuraishi Y. Expression of Fcε receptor I on primary sensory neurons in mice. Neuroreport 2004;15: 2029–2031.PubMedGoogle Scholar
  199. 199.
    Fabian RH, Ritchie TC. Intraneuronal IgG in the central nervous system. J Neurol Sci 1986;73: 257–267.PubMedGoogle Scholar
  200. 200.
    Fabian RH, Petroff G. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology 1987; 37: 1780–1784.PubMedGoogle Scholar
  201. 201.
    Dietzschold B, Kao M, Zheng YM, et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system [Erratum in: Proc Natl Acad Sci U S A 1992;89:9365]. Proc Natl Acad Sci U S A 1992;89: 7252–7256.PubMedGoogle Scholar
  202. 202.
    Aihara N, Tanno H, Hall JJ, Pitts LH, Noble LJ. Immunocytochemical localization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J Comp Neurol 1994;342: 481–496.PubMedGoogle Scholar
  203. 203.
    Mohamed HA, Mosier DR, Zou LL, et al. Immunoglobulin Fcγ receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 2002;69: 110–116.PubMedGoogle Scholar
  204. 204.
    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93: 2645–2668.PubMedGoogle Scholar
  205. 205.
    Masliah E, Rockenstein E, Adame A, et al. Effects of α-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005;46: 857–868.PubMedGoogle Scholar
  206. 206.
    Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after A/342 immunization. Neurology 2003;61: 46–54.PubMedGoogle Scholar
  207. 207.
    Connell JW, Rodriguez-Martin T, Gibb GM, et al. Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain Res Mol Brain Res 2005;137: 104–109.PubMedGoogle Scholar
  208. 208.
    Ishizawa K, Ksiezak-Reding H, Davies P, et al. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer’s disease, progressive supranuclear palsy and Pick’s disease. Acta Neuropathol 2000;100: 235–244.PubMedGoogle Scholar
  209. 209.
    Buée L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol 1999;9: 681–693.PubMedGoogle Scholar
  210. 210.
    Takanashi M, Mori H, Arima K, Mizuno Y, Hattori N. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res 2002;104: 210–219.PubMedGoogle Scholar
  211. 211.
    Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Over-expression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Ann Neurol 1999;46: 325–332.PubMedGoogle Scholar
  212. 212.
    Caffrey TM, Joachim C, Paracchini S, Esiri MM, Wade-Martins R. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet 2006;15: 3529–3537.PubMedGoogle Scholar
  213. 213.
    Boutajangout A, Boom A, Leroy K, Brion JP. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer’s disease. FEBS Lett 2004;576: 183–189.PubMedGoogle Scholar
  214. 214.
    Glatz DC, Rujescu D, Tang Y, et al. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer’s disease. J Neurochem 2006;96: 635–644.PubMedGoogle Scholar
  215. 215.
    Kalbfuss B, Mabon SA, Misteli T. Collection of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 2001;276: 42986–42993.PubMedGoogle Scholar
  216. 216.
    Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy [Erratum in: Nat Biotechnol 1999;17:602 and Nat Biotechnol 2001;19:277]. Nat Biotechnol 1999;17: 246–252.PubMedGoogle Scholar
  217. 217.
    Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, et al. Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci U S A 2005;102: 15659–15664.PubMedGoogle Scholar
  218. 218.
    Liu X, Jiang Q, Mansfield SG, et al. Partial collection of endogenous AF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 2002; 20: 47–52.PubMedGoogle Scholar
  219. 219.
    Chao H, Mansfield SG, Bartel RC, et al. Phenotype collection of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 2003;9: 1015–1019.PubMedGoogle Scholar
  220. 220.
    Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999;24: 751–762.PubMedGoogle Scholar
  221. 221.
    Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91: 479–487.PubMedGoogle Scholar
  222. 222.
    Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 2005;102: 227–231.PubMedGoogle Scholar
  223. 223.
    Michaelis ML, Seyb KI, Ansar S. Cytoskeletal integrity as a drug target. Curr Alzheimer Res 2005;2: 227–229.PubMedGoogle Scholar
  224. 224.
    Michaelis ML. Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice. Curr Alzheimer Res 2006;3: 215–219.PubMedGoogle Scholar
  225. 225.
    Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule interacting agent, NAP, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther 2008;325: 146–153.PubMedGoogle Scholar
  226. 226.
    Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer’s disease mouse model. Science 2007;316: 750–754.PubMedGoogle Scholar
  227. 227.
    Hutton M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001;56: S21-S25.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2008

Authors and Affiliations

  1. 1.Department of Psychiatry and PsychotherapyUniversity of GoettingenGoettingenGermany
  2. 2.Max-Planck-Institute for Experimental MedicineGoettingenGermany
  3. 3.Max-Planck-Unit for Structural Molecular Biology, c/o DESYHamburgGermany

Personalised recommendations